Status:
COMPLETED
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
Lead Sponsor:
Pfizer
Conditions:
Encephalitis, Tick-borne
Eligibility:
All Genders
6-47 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whet...
Eligibility Criteria
Inclusion
- Male and female children aged between 6 and 47 months
- No history of any previous TBE vaccination
- Clinically healthy
- Informed consent provided by the parents
Exclusion
- History of allergic reactions, in particular allergic reactions to one of the components of the vaccine
- Suffering from a disease that cannot be effectively treated or stabilised
- Suffering from a disease or undergoing a form of treatment which can be expected to influence immunological functions
- Suffering from a chronic, degenerative and/or inflammatory disease of the central nervous system
- HIV-positivity (no special HIV test required for the purpose of the study)
- Suffering from a febrile disease
- History of vaccination against yellow fever and/or Japanese encephalitis
- Participation in another clinical trial
Key Trial Info
Start Date :
April 1 1998
Trial Type :
INTERVENTIONAL
End Date :
June 1 1999
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00161746
Start Date
April 1 1998
End Date
June 1 1999
Last Update
May 21 2015
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Wiener Strasse 50/2
Kapfenberg, Austria, 8605
2
Erzherzog Johann Strasse 9
Leoben, Austria, 8700
3
Fronleichnamsweg 10
Liezen, Austria, 8940
4
Hauptstrasse 61
Linz, Austria, 4040